Cytologic malignancy versus benignancy: How useful are the "newer" markers in body fluid cytology?

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 1, 2008, Pages 23-28

  Lyons Boudreaux, Virganeyce ^a,c   Mody, Dina R ^b   Zhai, Jim ^b   Coffey, Donna ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CALRETININ; FORMALDEHYDE; PARAFFIN; PROTEIN D2 40; PROTEIN MOC 31; UNCLASSIFIED DRUG; WT1 PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ADENOCARCINOMA; ARTICLE; BODY FLUID; CELL PROLIFERATION; CYTOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EFFUSION; EPITHELIUM CELL; GRANULAR CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MESOTHELIUM; MESOTHELIUM CELL; METASTASIS; PERITONEUM; PLEURA EFFUSION; SENSITIVITY AND SPECIFICITY; STAINING;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; BODY FLUIDS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; HUMANS; HYPERPLASIA; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 38049074460     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunohistochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
2. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan JP. Immunohistochemistry in the differential diagnosis of serous effusions, a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer Cytopathol. 2001;93:68-72.
3. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol. 2001;25:158-0161.
4. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol. 2005;32:151-155.
5. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-Cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol. 1999;20:125-130.
6. Hecht JL, Lee BH, Pinkus JL, Pinkus GS. The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma. Cancer Cytopathol. 2002;96:105-109.
7. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.
8. Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary adenocarcinoma with pleural involvement. Diagn Cytopathol. 2006;34:801-806.
9. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407-1414.
10. Oates J, Edwards C. HBME-1, MOC-31, WT1, and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341-347.
11. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23:110-118.
12. Waldstrom M, Grove A. Immunohistochemical expression of Wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med. 2005;129:85-88.
13. Lee BH, Hecht JL, Pinkus JL, Pinkus GS. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
14. Hecht JL, Pinkus JL, Pinkus GS. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Cancer Cytopathol. 2006;108:56-59.
15. Morgan RL, DeYoung BR, McGaughy VR, Niemann TH. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer Cytopathol. 1999;87:390-394.
16. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE. Immunohistochemical detection of XIAP in body cavity effusions and washes. Mod Pathol. 2005;18:1618-1622.
17. Queiroz C, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions: the role of immunohistochemistry. Acta Cytol. 2001;45:18-22.
18. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol. 1997;17:115-120.
19. Bailey ME, Brown RW, Mody DR, Cagle P, Ramzy I. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions: comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Acta Cytol. 1996;40:1212-1216.
20. Barberis MCP, Faleri M, Veronese S, Casadio C, Viale G. Calretinin, a selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol. 1997;41:1757-1761.
21. Sun YX, Wu M, Desman GT, Gan L, Gil J, Burstein DE. XIAP immunostaining distinguishes malignant mesothelioma from benign mesothelial hyperplasia. Mod Pathol. 2006;19:318A. Abstract 1483.